This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
The Zacks Analyst Blog Highlights: Home Depot, Walmart, UnitedHealth, McDonald's and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Walmart, UnitedHealth, McDonald's and Johnson & Johnson
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Will Dow Gather Pace on the Latest 'Golden Cross' Formation?
by Nalak Das
The primary reason for the Dow lagging its peers is the weight of technology stocks within the indexes.
Stock Market News for Aug 6, 2020
by Zacks Equity Research
Wall Street closed higher on Wednesday supported by some developments regarding Congressional negotiations on a second round of fiscal stimulus.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Bayer (BAYRY) Q2 Earnings & Sales Fall Y/Y, Guidance Tweaked
by Zacks Equity Research
Bayer's (BAYRY) earnings and sales fall year over year in the second quarter of 2020.
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
by Zacks Equity Research
Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
by Zacks Equity Research
Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View
by Zacks Equity Research
Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.
Glaxo (GSK) Q2 Earnings & Sales Miss Estimates, Decline Y/Y
by Zacks Equity Research
Glaxo (GSK) witnesses disruption from COVID-19 pandemic in Vaccines and reversal of stockpiling benefits from the first quarter in Pharmaceuticals and Consumer Healthcare, which hurt sales.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q2 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.
How Damaging Will Coronavirus be for AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on AbbVie's (ABBV) performance when it reports second-quarter results.
Emergent (EBS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.